EORTC Soft Tissue and Bone Sarcoma Group

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
62006
Exatecan as second line treatment in advanced adult soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone sarcoma Group. (Study only open for patients with Leiomyosarcoma)
62011
Efficacy and safety study of Brostallicin in patients with locally advanced or metastatic soft tissue sarcoma failing one prior chemotherapy treatment
62002
Phase I study to determine the safety of Caelyx (Doxorubicin HCI, pegylated liposomal) in combination with Ifosfamide in previously untreated adult patients with advanced and/or metastatic soft tissues sarcomas.
62001
Dose finding and phase II study of STI 571 in advanced soft tissue sarcoma.
62982
Phase II study on ET-743 in advanced soft tissue sarcomas of the adult.
62972
Phase II Study on Gemcitabine in advanced soft tissue sarcomas of the adult
62971
Randomized phase III trial of two investigational schedules of Ifosfamide versus standard dose Doxorubicin in patients with advanced or metastatic soft tissue sarcoma.
62962
Phase II Study of Caelyx (Doxorubicin HCl, pegylated liposomal) or Doxorubicin in previously untreated adult patients with advanced and/or metastatic soft tissue sarcomas.
62953
Phase II study on HD Ifosfamide in advanced soft tissue sarcomas of the adult
62922
Phase II trial of temozolomide in adult patients with advanced soft tissue sarcoma
62941
Randomized multicenter phase III trial comparing Docetaxel to Doxorubicin in previously untreated patients with advanced and/or metastatic soft tissue sarcoma
62932
Phase II study of daily oral vepeside (etoposide VP16-213) as second line treatment in advanced soft tissue sarcomas
80931
EORTC/MRC/SIOP/UKCCSG/CSG collaborative phase III randomized trial of chemotherapy with or without granulocyte colony-stimulating factor in operable osteosarcoma
62921
A phase II trial with taxotere (RP56976) in advanced soft tissue sarcomas of the adult
62903
Randomized phase III study comparing conventional dose Doxorubicin plus Ifosfamide vs high dose Doxorubicin plus Ifosfamide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in the treatment of advanced soft tissue sarcomas in adults
62911
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcoma of the adult
62901
Randomized phase II-III study comparing adriamycin versus two schedules of high dose Epirubicin in advanced soft tissue sarcoma
62883
Phase II clinical study of the use of granulocyte-macrophage colony-stimulating factor (GM-CSF) with chemotherapy (adriamycin andifosfamide) in the treatment of advanced soft tissue sarcomas in adults
62882
PHASE II TRIAL OF FOTEMUSTINE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
62881
PHASE II STUDY OF ACNU IN METASTATIC SOFT TISSUE SARCOMA
62862
Phase II study of Iproplatin in advanced Osteogenic Sarcoma
62851
Phase III trial of first line chemotherapy (adriamycin vs adriamycin + ifosfamide vs cyvadic) in advanced soft tissue sarcoma
62832
Phase II study of Ifosfamide in advanced osteosarcoma
62771
Randomized trial for Adjuvant Chemotherapy in soft tissue sarcoma
62043
Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma
62005
Phase III randomised, intergroup, international trial assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing the KIT receptor tyrosine kinase (CD117)
62961
Randomized study comparing neoadjuvant chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) combined with regional hyperthermia (RHT) Vs neoadjuvant chemotherapy alone in the treatment of high-risk soft tissue sarcomas in adults. An Intergroup study with the European Society for hyperthermic oncology.
62061
Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma
62024
Intermediate and high risk localized,completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor : a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery.
62027
Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22) (q22;q13) translocation resulting in a COL1A1/PDGF- beta fusion protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF)
62931
Randomized phase III trial of adjuvant chemotherapy with high-dose doxorubicin, ifosfamide and lenograstim in high grade soft tissue sarcoma.
62022
Phase 2 study of Iressa (ZD 1839) in locally advanced and/or metastatic synovial sarcoma expressing HER1/EGFRI.
62991
Phase II pilot study of moderate dose radiotherapy for inoperable aggressive fibromatosis
62981
EURO-EWING 99 EUROpean Ewing tumour Working Initiative of National Groups Ewing Tumour Studies 1999
62933
Metastasectomy and chemotherapy for lung metastases from soft tissue sarcoma. A randomized phase III study (an Intergroup Study with the Scandinavian Sarcoma Group)
62091
A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3-hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma
62063
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.
62072
A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy.
62052
Phase II study of E7389 administered as an IV infusion on day 1 and 8 every 3 weeks in pretreated patients with advanced and/or metastatic soft tissue sarcoma
62012
Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma
62993
A phase II study to evaluate the role of weekly Cisplatin with oral Etoposide in Ewing's sarcoma and primitive neuroectodermal tumour (PNET) with metastasis outside the lung and the pleura.
62951
Phase II study on Tomudex in advanced soft tissue sacromas of the adult
62912
Randomized phase II study comparing two different Ifosfamide dose regimens
62902
PHASE II STUDY OF DAILY ORAL MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN ADVANCED SOFT TISSUE SARCOMAS OF THE ADULT.
62874
Randomized phase II study of neoadjuvant chemotherapy in soft tissue sarcomas in adults
62871
Phase II Chemotherapy with m-Azidopyrimethamine in Adults with Metastatic Soft Tissue Sarcoma (Summary Last Modified 05/88)
62863
Phase II study of Mitozolomide in metastatic soft tissue sarcoma
62861
Phase II Chemotherapy with Methylene Dimethane Sulphonate in Patients with Soft Tissue Sarcomas

Back to Group-list